Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
158.5 USD | -3.32% | -8.69% | +27.78% |
Apr. 16 | Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating | MT |
Mar. 12 | Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 84.3 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.78% | 4.68B | C | ||
-3.10% | 102B | B+ | ||
+2.11% | 96.07B | B+ | ||
-1.80% | 21.66B | B | ||
-17.75% | 20.77B | B+ | ||
-6.91% | 18.53B | A- | ||
-42.00% | 16.91B | A- | ||
-28.19% | 13.79B | B | ||
+0.18% | 13.33B | C+ | ||
+19.90% | 10.94B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KRYS Stock
- Ratings Krystal Biotech, Inc.